10x Genomics Lifts Full-Year Revenue Guidance After Q3 Beat, Atera Ramp Begins
TXG has more than doubled off its 52-week low of $12.8.
Summary
10x Genomics raised full-year 2026 revenue guidance to $625M-$635M from $610M-$630M after Q3 revenue came in at $150.7M, up 1% year over year. Gross margin jumped to 75% from 67% on lower inventory write-downs and better product mix, and the net loss narrowed to $19.4M from $27.5M, with the quarterly loss per share at 15c. The quarter's real story is Atera: the next-generation spatial platform began global commercial shipments, following the September launch announcement, and management called early demand extraordinary. Consumables carried the top line — spatial consumables rose to $41.2M from $35.4M — while instrument revenue fell to $6.9M from $12.0M, a mix shift that supports margins. The company also introduced Sentira, a cloud analysis platform built on NVIDIA computing and Anthropic's Claude. Cash and marketable securities stood at $575.7M, giving ample runway against the current loss run rate.
At the time of this announcement, TXG was trading at $57.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $12.80 to $102.81. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.